A5056665543- COVID-19 and healthcare impacts
- Lung Cancer Treatments and Mutations
- COVID-19 Clinical Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Neutropenia and Cancer Infections
- Global Cancer Incidence and Screening
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Cancer Treatment and Pharmacology
- Frailty in Older Adults
- Advanced Breast Cancer Therapies
- Infection Control and Ventilation
- Radiomics and Machine Learning in Medical Imaging
- Venous Thromboembolism Diagnosis and Management
- Histone Deacetylase Inhibitors Research
- DNA Repair Mechanisms
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- MRI in cancer diagnosis
Missouri Baptist Medical Center
2016-2024
Heartland Cancer Research
2019-2023
Hematology Oncology Consultants
2022
IHA Hematology Oncology Consultants
2022
American Society of Clinical Oncology
2016
Virginia Cancer Specialists
2016
Aurora Health Care
2016
Fox Chase Cancer Center
2009-2011
Temple University Hospital
2010
Washington University in St. Louis
2008
PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor has yielded promising results multiple tumor types. METHODS In this randomized phase II Lung-MAP nonmatch substudy (S1800A), patients ineligible for biomarker-matched NSCLC previously treated and platinum-based chemotherapy progressive disease at least 84 days after initiation of were...
<h3>Importance</h3> Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations are needed. <h3>Objective</h3> To assess whether the addition pembrolizumab during after chemoradiotherapy can lead an improvement in (NAR) score compared with treatment FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) alone. <h3>Design,...
8506 Background: First line therapy options for advanced NSCLC without actionable molecular alterations include immunotherapy (IO) -/+ chemotherapy or alone. NRG-LU002 was a randomized phase II/III study assessing the benefits of local consolidative (LCT) when added to systemic as maintenance in management oligometastatic NSCLC. Methods: Eligible patients had metastatic with 3 fewer extracranial sites (excluding primary) exhibiting at least stable disease after 4 cycles 1 st therapy....
Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement progression-free survival (PFS) and overall (OS) addition entinostat to steroidal aromatase inhibitor (AI) exemestane hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative cancer.
Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to worse outcomes associated during the pandemic. We sought evaluate clinical characteristics and patients who developed breakthrough after 2 or 3 doses mRNA vaccines.
8504 Background: In unselected patients (pts) with extensive-stage small cell lung cancer (ES-SCLC), the addition of immune checkpoint inhibitors (ICI) to chemotherapy resulted in a modest improvement OS. retrospective analysis study veliparib (PARP inhibitor [PARPi]) and temozolomide SCLC, Schlafen-11 (SLFN11) predicted PFS OS benefit for PARPi. We evaluated whether PARPi (talazoparib) standard-of-care maintenance ICI (atezolizumab) following frontline chemoimmunotherapy improved outcomes...
Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods to communicate magnitudes of regression during TNT are subjective and imprecise. Magnetic resonance tumor grade (MR-TRG) an existing, but rarely used, grading system. Prospective validation MR-TRG correlation with pathologic response in patients undergoing lacking. Utility adding diffusion-weighted imaging also unknown.
Abstract Background Early studies showed promise of combined anti-epidermal growth factor receptor (EGFR) plus anti–vascular endothelial (VEGF) antibodies for advanced colorectal cancer (CRC), yet this was later rejected as toxic and ineffective in not selected RAS status. We studied KRAS wild-type CRC, second-line treatment, using irinotecan-cetuximab with or without the anti-VEGF antibody ramucirumab. Methods Patients 1 prior regimen including fluoropyrimidine, oxaliplatin, bevacizumab,...
<h3>Importance</h3> Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing a potential tissue-based expression coreceptor transmembrane protease, serine 2 (TMPRSS2). <h3>Objective</h3> To examine whether ADT is associated decreased rate 30-day mortality from among cancer. <h3>Design, Setting, and Participants</h3> This cohort study analyzed patient data recorded COVID-19 Cancer Consortium registry between...
Background: Polypharmacy and potentially inappropriate medications (PIMs) are prevalent in older adults with cancer, but their associations physical function not often studied. This study examined the of polypharmacy PIMs determined optimal cutoff value for number most strongly associated functional impairment. Methods: cross-sectional analysis used baseline data from a randomized enrolling patients aged ≥70 years advanced cancer starting new systemic treatment. We categorized PIM using 2015...
Lung cancer remains the most frequently diagnosed in United States, excluding non-melanoma skin cancer. Non-small cell lung (NSCLC) constitutes majority (more than 80%) of diagnoses. Systemic therapy, with either cytotoxic chemotherapy and/or targeted therapies, has been established to provide benefit patients NSCLC both adjuvant and advanced disease settings. Vinorelbine, a semi-synthetic vinca-alkaloid extensively tested alone combination other or agents treatment NSCLC. Its safety well...
9004 Background: Resistance to immune checkpoint inhibitor (ICI) therapy develops in most patients (pts) with advanced non-small cell lung cancer (NSCLC). Tumors that develop resistance ICI constitute a major unmet need. Combined and VEGF/VEGF receptor inhibition have shown benefit multiple tumor types through modulation. We evaluated pembrolizumab ramucirumab (P+R) advanced, ICI-exposed NSCLC, under the aegis of Lung-MAP, master protocol for pts stage IV, previously treated NSCLC. Pt...
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy Bryan A Faller, Barbara BurtnessDepartment Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The receptor (EGFR) commonly expressed target involved tumor proliferation, metastasis, and induction angiogenesis....
Enthusiasm for precision oncology may obscure the psychosocial and ethical considerations associated with implementation of tumor genetic sequencing. Patients advanced cancer undergoing tumor-only sequencing in National Cancer Institute Molecular Analysis Therapy Choice (MATCH) trial were randomized to a web-based education intervention or usual care. The primary outcomes knowledge, anxiety, depression, cancer-specific distress collected at baseline (T0), posteducation (T1) after results...
2619 Background: IL-15 is a member of the IL-2 common gamma chain family cytokines. N-803 administered in complex with receptor alpha. Lung cancer, despite advances targeted therapies and immunotherapy, remains leading cause cancer related death United States. Strategies to improve performance immunotherapy advanced NSCLC clinical unmet need. Methods: Lung-MAP S1800D was randomized study comparing plus pembrolizumab (NP) investigators’ choice standard-of-care chemotherapy (SoC) for...
Background: Older adults (age ≥65 years) receiving chemotherapy are at risk for hospitalization. Predictors of unplanned hospitalization among older cancer were recently published using data from a study conducted by the Cancer and Aging Research Group (CARG). Our aimed to externally validate these predictors in an independent cohort including with advanced chemotherapy. Methods: This validation included patients (n=369) GAP70+ trial usual care arm. Enrolled aged ≥70 years incurable starting...
Purpose: Community-based research programs face many barriers to participation in clinical trials. Although the majority of people with cancer are diagnosed and treated community setting, only roughly 3% enrolled onto Research contract budget negotiations have been consistently identified as time consuming a barrier ASCO’s Community Forum conducted survey about specific challenges negotiation processes community-based settings. The goal was ultimately identify potential solutions these...
9024 Background: While prior studies have shown robust efficacy leading to FDA approval of PARP inhibitors (PARPi) in BRCA-associated cancers, data NSCLC are much less clear. S1900A, a LUNG-MAP substudy, evaluated the PARPi rucaparib advanced stage harboring BRCA1/2 mutations or genomic loss heterozygosity (LOH) as phenotypic marker homologous recombination deficiency (HRD). Methods: Eligible patients (pts) were required deleterious mutation BRCA1/BRCA2 and/or high (≥21%) LOH. Key...
A key issue for the adjuvant treatment of patients with melanoma is assessment effect on relapse, survival, and quality life (QOL).To compare QOL in resected at high risk relapse who were treated pembrolizumab vs standard care either ipilimumab or high-dose interferon α 2b (HDI).The S1404 phase 3 randomized clinical trial was conducted by SWOG Cancer Research Network 211 community/academic sites US, Canada, Ireland. Patients enrolled from December 2015 to October 2017. Data analysis this...
This 45-year-old woman presented with progressive distal finger enlargement and polyarthralgias.